OBJECTIVE: Overexpression of @entity588 is a mechanism of drug resistance in @entity5 . Agents that down-regulate @entity588 may decrease @entity5 cell threshold and sensitize @entity5 cells to chemotherapy. The objective of this multi-institutional phase 2 trial was to evaluate the efficacy and @entity137 of @entity1311 and @entity588 modulators (13-cis @entity1968 and interferon alfa-2b) in @entity1 with advanced-stage or recurrent @entity5 . MATERIALS AND METHODS: @entity1 had biopsy-proven metastatic, first relapse, or persistent @entity5 with no prior chemotherapy except for chemosensitizing agents. The treatment consisted of oral 13-cis @entity1968 , 1 mg/kg, and subcutaneous interferon alfa-2b, 6 mU/m, days 1 to 4, and intravenous @entity1311 , 175 mg/m, day 4 until disease progression or adverse events prohibited treatment. The primary endpoint was overall response rate. RESULTS: Thirty-three @entity1 were enrolled between March 2001 and June 2009. Thirty-one @entity1 were eligible for evaluation of treatment response. Twenty-seven @entity1 (82%) received prior concurrent chemoradiation or radiotherapy alone before study enrollment. The overall response rate was 30% (6 complete responses and 4 partial responses). Furthermore, 7 @entity1 (21%) had stable disease. Grade 3 or 4 adverse events included @entity1398 (n =16 [48%]), @entity1398 (n = 1 [3%]), and @entity417 (n = 1 [3%]). There were no treatment-related @entity204 . The median progression-free survival was 3.4 months (95% confidence interval, 2.0-7.4 months), and overall survival was 11.2 months (95% confidence interval, 7.5-26.2 months). Of 6 @entity1 with complete responses, 5 @entity1 survived more than 2 years. CONCLUSIONS: Combination therapy with @entity1311 , 13-cis @entity1968 , and interferon alfa-2b is feasible and safe in treating @entity1 with advanced and recurrent @entity5 .

Phase 2 Trial of @entity1311 , 13-cis XXXX , and Interferon Alfa-2b in the Treatment of Advanced Stage or Recurrent @entity5 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity588 :: ('596', 'Gene') :: ['bcl-2'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anemia'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cervical cancer'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia', 'febrile neutropenia'] @entity204 :: ('MESH:D003643', 'Disease') :: ['deaths'] @entity1968 :: ('MESH:D014212', 'Chemical') :: ['retinoic acid']
@entity1968 :: (MESH:D014212,Chemical) :: ['Retinoic Acid']
